Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. April 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Castle announces 4th Top Workplaces USA win, ranking 30th of 358 U.S. companies with 500-999 employees
03. April 2025 07:00 ET | Quelle: Castle Biosciences, Inc.

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Castle announced the recent publication of prospective data demonstrating the significant impact of DecisionDx-Melanoma on SLNB decision-making.
01. April 2025 16:30 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle will present data on DecisionDx-Melanoma at the 11th World Congress of Melanoma and 21st European Association of Dermato-Oncology (EADO) Congress.
28. März 2025 16:15 ET | Quelle: Castle Biosciences, Inc.

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference.

Vorherige Seite